Ranibizumab: treatment in patients with neovascular age-related macular degeneration.

Article Details

Citation

Copy to clipboard

Pieramici DJ, Avery RL

Ranibizumab: treatment in patients with neovascular age-related macular degeneration.

Expert Opin Biol Ther. 2006 Nov;6(11):1237-45.

PubMed ID

17049020 [ View in PubMed

]

Abstract

Vascular endothelial growth factor (VEGF)-A is a major regulator of angiogenesis and vascular permeability implicated in the development of diseases involving pathological angiogenesis and increased vascular permeability, such as neovascular age-related macular degeneration (AMD). LUCENTIS (ranibizumab), a humanized antigen-binding fragment (Fab) that neutralizes all VEGF-A isoforms and their biologically active degradation products, was recently approved by the FDA. Ranibizumab is the first FDA-approved treatment for neovascular AMD that maintains or improves vision in > or = 90% patients and provides a > or = 15-letter improvement in visual acuity for a quarter to a third of patients with all choroidal neovascularisation subtypes. Ranibizumab was associated with a < or = 1.7% rate of key serious ocular adverse events, such as endophthalmitis and uveitis, in two pivotal Phase III trials.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Ranibizumab	Vascular endothelial growth factor A	Protein	Humans	Yes	Antibody	Details